Huron Announces Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Guidance

Huron Announces Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Guidance

FOURTH QUARTER 2020 HIGHLIGHTS

  • Revenues were $198.3 million in Q4 2020 compared to $232.3 million in Q4 2019.
  • Net loss from continuing operations, which includes $18.7 million of restructuring charges related to the fourth quarter 2020 restructuring plan, was $6.1 million in Q4 2020 compared to net income from continuing operations of $14.4 million in Q4 2019.
  • Adjusted EBITDA(7), a non-GAAP measure, was $17.1 million in Q4 2020 compared to $29.4 million in Q4 2019.
  • Diluted loss per share from continuing operations was $0.28 in Q4 2020 compared to diluted earnings per share from continuing operations of $0.63 in Q4 2019.
  • Adjusted diluted earnings per share from continuing operations(7), a non-GAAP measure, was $0.45 in Q4 2020 compared to $0.79 in Q4 2019.
  • Cash flows from operating activities were $58.7 million in Q4 2020, which were primarily used to repay $48.0 million of outstanding borrowings on the company’s revolving credit facility.

FULL YEAR 2020 HIGHLIGHTS AND 2021 GUIDANCE

  • Revenues were $844.1 million for full year 2020 compared to $876.8 million for full year 2019.
  • Net loss from continuing operations, which includes non-cash pretax goodwill impairment charges of $59.8 million related to the company’s Strategy and Innovation and Life Sciences reporting units within the Business Advisory segment incurred in Q1 2020 and $18.7 million of restructuring charges related to the fourth quarter 2020 restructuring plan, was $23.7 million for full year 2020 compared to net income from continuing operations of $42.0 million for full year 2019.
  • Adjusted EBITDA(7), a non-GAAP measure, was $87.1 million for full year 2020 compared to $105.4 million for full year 2019.
  • Diluted loss per share from continuing operations was $1.08 for full year 2020 compared to diluted earnings per share from continuing operations of $1.87 for full year 2019.
  • Adjusted diluted earnings per share from continuing operations(7), a non-GAAP measure, was $2.15 for full year 2020 compared to $2.74 for full year 2019.
  • Cash flows from operating activities increased 3.4% to $136.7 million for full year 2020 compared to $132.2 million for full year 2019.
  • Huron provides full year 2021 guidance, including revenue expectations in a range of $830.0 million to $890.0 million.

 

CHICAGO–(BUSINESS WIRE)–
Global professional services firm Huron (NASDAQ: HURN) today announced financial results from continuing operations for the fourth quarter and full year ended December 31, 2020.

“While we didn’t achieve our growth objectives set prior to the pandemic, Huron’s response during the pandemic was strengthened by our collective resiliency and market relevancy amidst the incredible challenges that faced our client base. Our people were proactive, innovative and nimble in helping our clients quickly respond to new challenges brought on by the pandemic. Our ability to rapidly bring to market creative solutions to these new challenges enabled us to generate over $30 million in revenue from these services in 2020,” said James H. Roth, chief executive officer of Huron. “Our Business Advisory segment achieved record revenues in 2020, driven by increased demand for our digital, technology and analytics and distressed advisory offerings as organizations transform their businesses to compete in more disruptive environments. Our strategic investments in the Business Advisory segment are accelerating our growth in commercial markets, enabling a balanced portfolio across our services and end markets.”

“As organizations evaluate changes to their own businesses stemming from the impacts of the pandemic, we believe we are well positioned to help our clients accelerate operational, digital and cultural transformation to achieve successful and sustainable results in the coming years,” added Roth.

COVID-19 IMPACT

The worldwide spread of the coronavirus (COVID-19) has created significant volatility, uncertainty and disruption to the global economy. The company continues to closely monitor the impact of the pandemic on all aspects of its business, including how it will impact its clients, employees and business partners. In 2020, some clients reprioritized and delayed projects as a result of the pandemic. This negatively impacted demand for certain services, primarily in the company’s Healthcare and Education segments. Conversely, the pandemic strengthened demand for cloud-based technology and analytics solutions and certain services provided to organizations in transition within the company’s Business Advisory segment.

During the second half of 2020, the pandemic continued to negatively impact sales and elongate the sales cycle for new opportunities for certain services, particularly within the company’s Healthcare and Education segments. Given the uncertainties around the duration of the COVID-19 pandemic, the company continues to remain cautious about revenue growth for the first half of 2021, which is contemplated in the 2021 guidance provided.

FOURTH QUARTER 2020 RESTRUCTURING PLAN

On October 29, 2020, the company announced a restructuring plan to reduce operating costs to address the impact of the COVID-19 pandemic on its business. The restructuring plan, which was substantially complete in the fourth quarter of 2020, provided for a reduction in workforce and leased office space. The company does not anticipate a material revenue impact related to the restructuring actions.

The reduction in workforce impacted approximately 125 employees across all segments and corporate operations. The company incurred a $4.8 million restructuring charge related to cash payments for employee severance and benefits. As a result of the reduction in workforce, the company expects to realize annualized savings of approximately $21.0 million related to employee salaries and related benefits. Additional cost avoidance measures, including limiting annual salary increases, are expected to result in additional annualized savings.

The reduction in leased office space resulted in non-cash lease impairment charges of $13.9 million. The company does not expect to incur additional, significant lease impairment charges in 2021 related to the plan; however, any significant decline in the estimated amount or delayed timing of sublease income could result in additional non-cash lease impairment charges through the end of the lease terms. Future cash expenditures related to the leased office space are expected to continue through 2029. As a result of the reduction in leased office space, the company expects to realize annualized savings of approximately $1.0 million in lease-related expense, and expects approximately $2.5 million of ongoing lease-related costs to be reflected as restructuring charges in 2021.

The company believes these measures will better align delivery capacity with anticipated demand and strengthen the company’s financial position amidst the ongoing disruption, creating a foundation from which it can grow.

FOURTH QUARTER 2020 RESULTS FROM CONTINUING OPERATIONS

Revenues were $198.3 million for the fourth quarter of 2020, compared to $232.3 million for the fourth quarter of 2019.

Net loss from continuing operations was $6.1 million for the fourth quarter of 2020 compared to net income from continuing operations of $14.4 million for the same quarter last year. Diluted loss per share from continuing operations was $0.28 for the fourth quarter of 2020 compared to diluted earnings per share from continuing operations of $0.63 for the fourth quarter of 2019. Results for the fourth quarter of 2020 reflect $18.7 million of restructuring charges related to the fourth quarter 2020 restructuring plan discussed above.

Fourth quarter 2020 loss before interest, taxes, depreciation and amortization(7) was $1.9 million compared to earnings before interest, taxes, depreciation and amortization of $29.1 million in the same prior year period.

In addition to using earnings (loss) before interest, taxes, depreciation and amortization (“EBITDA”) to evaluate the company’s financial performance, management uses other non-GAAP financial measures, which exclude the effect of the following items (in thousands):

 

Three Months Ended

December 31,

 

2020

 

2019

Amortization of intangible assets

$

3,138

 

 

$

4,757

 

Restructuring and other charges (gains)

$

18,748

 

 

$

(301

)

Litigation and other losses

$

 

 

$

375

 

Transaction-related expenses

$

695

 

 

$

67

 

Unrealized gain on preferred stock investment

$

(1,667

)

 

$

 

Loss on sale of business

$

1,501

 

 

$

 

Tax effect of adjustments

$

(6,158

)

 

$

(1,291

)

Foreign currency transaction losses (gains), net

$

(276

)

 

$

124

 

Adjusted EBITDA(7) was $17.1 million, or 8.6% of revenues, in the fourth quarter of 2020, compared to $29.4 million, or 12.6% of revenues, in the same prior year period. Adjusted net income from continuing operations(7) was $10.2 million, or $0.45 per diluted share, for the fourth quarter of 2020, compared to $18.0 million, or $0.79 per diluted share, for the same prior year period.

The average number of full-time billable consultants(1) increased 1.7% to 2,626 in the fourth quarter of 2020 from 2,582 in the same quarter last year. Full-time billable consultant utilization rate(2) was 68.0% during the fourth quarter of 2020 compared to 75.0% during the same period last year. Average billing rate per hour for full-time billable consultants(3) was $217 for the fourth quarter of 2020 compared to $223 for the same prior year period. The average number of full-time equivalent professionals(5) was 355 in the fourth quarter of 2020 compared to 337 for the same period in 2019.

FULL YEAR 2020 RESULTS FROM CONTINUING OPERATIONS

Revenues were $844.1 million for full year 2020 compared to $876.8 million for full year 2019.

Net loss from continuing operations was $23.7 million for full year 2020, compared to net income from continuing operations of $42.0 million for full year 2019. Diluted loss per share from continuing operations was $1.08 for full year 2020, compared to diluted earnings per share from continuing operations of $1.87 for full year 2019. Results for full year 2020 reflect non-cash pretax charges totaling $59.8 million to reduce the carrying value of goodwill in the company’s Strategy and Innovation and Life Sciences reporting units within the Business Advisory segment. The impairment charges are non-cash in nature and do not affect the company’s liquidity or debt covenants. Additionally, in the fourth quarter of 2020, the company recognized $18.7 million of restructuring charges related to the fourth quarter 2020 restructuring plan discussed above.

EBITDA(7) was $5.1 million for full year 2020, compared to EBITDA of $101.9 million for full year 2019.

In addition to using EBITDA to evaluate the company’s financial performance, management uses other non-GAAP financial measures, which exclude the effect of the following items (in thousands):

 

Twelve Months Ended

December 31,

 

2020

 

2019

Amortization of intangible assets

$

12,696

 

 

$

17,793

 

Restructuring and other charges

$

21,374

 

 

$

1,855

 

Litigation and other gains, net

$

(150

)

 

$

(1,196

)

Transaction-related expenses

$

1,132

 

 

$

2,680

 

Goodwill impairment charges

$

59,816

 

 

$

 

Non-cash interest on convertible notes

$

 

 

$

6,436

 

Unrealized gain on preferred stock investment

$

(1,667

)

 

$

 

Losses on sales of businesses

$

1,603

 

 

$

 

Tax effect of adjustments

$

(23,199

)

 

$

(7,200

)

Tax benefit related to “check-the-box” election

$

 

 

$

(736

)

Foreign currency transaction losses (gains), net

$

(31

)

 

$

160

 

Adjusted EBITDA(7) was $87.1 million, or 10.3% of revenues, for full year 2020 compared to $105.4 million, or 12.0% of revenues, for full year 2019. Adjusted net income from continuing operations(7) was $47.9 million, or $2.15 per diluted share, for full year 2020 compared to $61.6 million, or $2.74 per diluted share, for full year 2019.

The average number of full-time billable consultants(1) increased 7.1% to 2,600 for full year 2020 from 2,427 for full year 2019, primarily related to hiring that occurred prior to the COVID-19 pandemic. Full-time billable consultant utilization rate(2) was 70.7% during 2020 compared to 76.1% during 2019. Average billing rate per hour for full-time billable consultants(3) was $208 for full year 2020 compared to $211 for full year 2019. The average number of full-time equivalent professionals(5) was 360 for full year 2020 compared to 305 for full year 2019.

OPERATING SEGMENTS

Huron’s results reflect a portfolio of service offerings focused on helping clients address complex business challenges.

The company’s full year 2020 revenues by operating segment as a percentage of total company revenues are as follows: Healthcare (42%); Business Advisory (32%); and Education (26%). Financial results by segment are included in the attached schedules and in Huron’s Annual Report on Form 10-K filing for the year ended December 31, 2020.

OUTLOOK FOR 2021

Based on currently available information, the company provided guidance for full year 2021 revenues before reimbursable expenses in a range of $830.0 million to $890.0 million. The company anticipates adjusted EBITDA as a percentage of revenues in a range of 10.8% to 11.8% and non-GAAP adjusted diluted earnings per share in a range of $2.25 to $2.75.

Management will provide a more detailed discussion of its outlook during the company’s earnings conference call webcast.

FOURTH QUARTER 2020 WEBCAST

The company will host a webcast to discuss its financial results today, February 23, 2021, at 5:00 p.m. Eastern Time (4:00 p.m. Central Time). The conference call is being webcast by NASDAQ and can be accessed from Huron’s website at http://ir.huronconsultinggroup.com. A replay will be available approximately two hours after the conclusion of the webcast and for 90 days thereafter.

USE OF NON-GAAP FINANCIAL MEASURES(7)

In evaluating the company’s financial performance and outlook, management uses EBITDA, adjusted EBITDA, adjusted EBITDA as a percentage of revenues, adjusted net income from continuing operations, and adjusted diluted earnings per share from continuing operations, which are non-GAAP measures. Management uses these non-GAAP financial measures to gain an understanding of the company’s comparative operating performance (when comparing such results with previous periods or forecasts). These non-GAAP financial measures are used by management in their financial and operating decision making because management believes they reflect the company’s ongoing business in a manner that allows for meaningful period-to-period comparisons. Management also uses these non-GAAP financial measures when publicly providing their business outlook, for internal management purposes, and as a basis for evaluating potential acquisitions and dispositions. Management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating Huron’s current operating performance and future prospects in the same manner as management does, if they so choose, and in comparing in a consistent manner Huron’s current financial results with Huron’s past financial results. Investors should recognize that these non-GAAP measures might not be comparable to similarly titled measures of other companies. These measures should be considered in addition to, and not as a substitute for or superior to, any measure of performance, cash flows or liquidity prepared in accordance with accounting principles generally accepted in the United States.

Management has provided its outlook regarding adjusted EBITDA and non-GAAP adjusted diluted earnings per share, both of which are non-GAAP financial measures and exclude certain charges. Management has not reconciled these non-GAAP financial measures to the corresponding GAAP financial measures because guidance for the various reconciling items are not provided. Management is unable to provide guidance for these reconciling items because we cannot determine their probable significance, as certain items are outside of the company’s control and cannot be reasonably predicted since these items could vary significantly from period to period. Accordingly, reconciliations to the corresponding GAAP financial measures are not available without unreasonable effort.

ABOUT HURON

Huron is a global consultancy that collaborates with clients to drive strategic growth, ignite innovation and navigate constant change. Through a combination of strategy, expertise and creativity, we help clients accelerate operational, digital and cultural transformation, enabling the change they need to own their future. By embracing diverse perspectives, encouraging new ideas and challenging the status quo, we create sustainable results for the organizations we serve. Learn more at www.huronconsultinggroup.com.

Statements in this press release that are not historical in nature, including those concerning the company’s current expectations about its future results, are “forward-looking” statements as defined in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by words such as “may,” “should,” “expects,” “provides,” “anticipates,” “assumes,” “can,” “will,” “meets,” “could,” “likely,” “intends,” “might,” “predicts,” “seeks,” “would,” “believes,” “estimates,” “plans,” “continues,” “guidance,” or “outlook” or similar expressions. These forward-looking statements reflect the company’s current expectations about future requirements and needs, results, levels of activity, performance, or achievements. Some of the factors that could cause actual results to differ materially from the forward-looking statements contained herein include, without limitation: the impact of the COVID-19 pandemic on the economy, our clients and client demand for our services, and our ability to sell and provide services, including the measures taken by governmental authorities and businesses in response to the pandemic, which may cause or contribute to other risks and uncertainties that we face; failure to achieve expected utilization rates, billing rates and the number of revenue-generating professionals; inability to expand or adjust our service offerings in response to market demands; our dependence on renewal of client-based services; dependence on new business and retention of current clients and qualified personnel; failure to maintain third-party provider relationships and strategic alliances; inability to license technology to and from third parties; the impairment of goodwill; various factors related to income and other taxes; difficulties in successfully integrating the businesses we acquire and achieving expected benefits from such acquisitions; risks relating to privacy, information security, and related laws and standards; and a general downturn in market conditions. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, including, among others, those described under Item 1A. “Risk Factors” in Huron’s Annual Report on Form 10-K for the year ended December 31, 2020, that may cause actual results, levels of activity, performance or achievements to be materially different from any anticipated results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. The company disclaims any obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

HURON CONSULTING GROUP INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)

(In thousands, except per share amounts)

(Unaudited)

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

 

2020

 

2019

 

2020

 

2019

Revenues and reimbursable expenses:

 

 

 

 

 

 

 

Revenues

$

198,347

 

 

$

232,269

 

 

$

844,127

 

 

$

876,757

 

Reimbursable expenses

1,754

 

 

22,930

 

 

26,887

 

 

88,717

 

Total revenues and reimbursable expenses

200,101

 

 

255,199

 

 

871,014

 

 

965,474

 

Direct costs and reimbursable expenses (exclusive of depreciation and amortization shown in operating expenses):

 

 

 

 

 

 

 

Direct costs

141,207

 

 

153,160

 

 

592,428

 

 

575,602

 

Amortization of intangible assets and software development costs

1,361

 

 

1,925

 

 

5,366

 

 

5,375

 

Reimbursable expenses

1,823

 

 

22,799

 

 

26,918

 

 

88,696

 

Total direct costs and reimbursable expenses

144,391

 

 

177,884

 

 

624,712

 

 

669,673

 

Operating expenses and other losses (gains), net:

 

 

 

 

 

 

 

Selling, general and administrative expenses

43,822

 

 

51,662

 

 

170,686

 

 

203,071

 

Restructuring charges (gains)

18,748

 

 

(301

)

 

20,525

 

 

1,855

 

Litigation and other losses (gains), net

 

 

375

 

 

(150

)

 

(1,196

)

Depreciation and amortization

5,794

 

 

7,080

 

 

24,277

 

 

28,365

 

Goodwill impairment charges

 

 

 

 

59,816

 

 

 

Total operating expenses and other losses (gains), net

68,364

 

 

58,816

 

 

275,154

 

 

232,095

 

Operating income (loss)

(12,654

)

 

18,499

 

 

(28,852

)

 

63,706

 

Other income (expense), net:

 

 

 

 

 

 

 

Interest expense, net of interest income

(1,776

)

 

(2,492

)

 

(9,292

)

 

(15,648

)

Other income, net

3,584

 

 

1,603

 

 

4,271

 

 

4,433

 

Total other income (expense), net

1,808

 

 

(889

)

 

(5,021

)

 

(11,215

)

Income (loss) from continuing operations before taxes

(10,846

)

 

17,610

 

 

(33,873

)

 

52,491

 

Income tax expense (benefit)

(4,742

)

 

3,256

 

 

(10,155

)

 

10,512

 

Net income (loss) from continuing operations

(6,104

)

 

14,354

 

 

(23,718

)

 

41,979

 

Loss from discontinued operations, net of tax

(33

)

 

(41

)

 

(122

)

 

(236

)

Net income (loss)

$

(6,137

)

 

$

14,313

 

 

$

(23,840

)

 

$

41,743

 

Net earnings (loss) per basic share:

 

 

 

 

 

 

 

Net income (loss) from continuing operations

$

(0.28

)

 

$

0.65

 

 

$

(1.08

)

 

$

1.91

 

Loss from discontinued operations, net of tax

 

 

 

 

(0.01

)

 

(0.01

)

Net income (loss)

$

(0.28

)

 

$

0.65

 

 

$

(1.09

)

 

$

1.90

 

Net earnings (loss) per diluted share:

 

 

 

 

 

 

 

Net income (loss) from continuing operations

$

(0.28

)

 

$

0.63

 

 

$

(1.08

)

 

$

1.87

 

Loss from discontinued operations, net of tax

 

 

 

 

(0.01

)

 

(0.02

)

Net income (loss)

$

(0.28

)

 

$

0.63

 

 

$

(1.09

)

 

$

1.85

 

Weighted average shares used in calculating earnings (loss) per share:

 

 

 

 

 

 

 

Basic

21,903

 

 

22,051

 

 

21,882

 

 

21,993

 

Diluted

21,903

 

 

22,676

 

 

21,882

 

 

22,507

 

Comprehensive income:

 

 

 

 

 

 

 

Net income (loss)

$

(6,137

)

 

$

14,313

 

 

$

(23,840

)

 

$

41,743

 

Foreign currency translation adjustments, net of tax

642

 

 

772

 

 

348

 

 

99

 

Unrealized gain (loss) on investment, net of tax

2,374

 

 

(8,442

)

 

1,323

 

 

(702

)

Unrealized gain (loss) on cash flow hedging instruments, net of tax

87

 

 

42

 

 

(3,546

)

 

(956

)

Other comprehensive income (loss)

3,103

 

 

(7,628

)

 

(1,875

)

 

(1,559

)

Comprehensive income (loss)

$

(3,034

)

 

$

6,685

 

 

$

(25,715

)

 

$

40,184

 

HURON CONSULTING GROUP INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

December 31,

2020

 

December 31,

2019

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

67,177

 

 

$

11,604

 

Receivables from clients, net

86,966

 

 

116,571

 

Unbilled services, net

61,181

 

 

79,937

 

Income tax receivable

5,121

 

 

2,376

 

Prepaid expenses and other current assets

16,569

 

 

14,248

 

Total current assets

237,014

 

 

224,736

 

Property and equipment, net

29,093

 

 

38,413

 

Deferred income taxes, net

4,191

 

 

1,145

 

Long-term investments

71,030

 

 

54,541

 

Operating lease right-of-use assets

39,360

 

 

54,954

 

Other non-current assets

62,068

 

 

52,177

 

Intangible assets, net

20,483

 

 

31,625

 

Goodwill

594,237

 

 

646,680

 

Total assets

$

1,057,476

 

 

$

1,104,271

 

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

648

 

 

$

7,944

 

Accrued expenses and other current liabilities

14,874

 

 

18,554

 

Accrued payroll and related benefits

133,830

 

 

141,605

 

Current maturities of long-term debt

499

 

 

529

 

Current maturities of operating lease liabilities

8,771

 

 

7,469

 

Deferred revenues

34,748

 

 

28,443

 

Total current liabilities

193,370

 

 

204,544

 

Non-current liabilities:

 

 

 

Deferred compensation and other liabilities

45,361

 

 

28,635

 

Accrued contingent consideration for business acquisitions

1,770

 

 

 

Long-term debt, net of current portion

202,780

 

 

208,324

 

Operating lease liabilities, net of current portion

61,825

 

 

69,233

 

Deferred income taxes, net

428

 

 

8,070

 

Total non-current liabilities

312,164

 

 

314,262

 

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Common stock; $0.01 par value; 500,000,000 shares authorized; 25,346,916 and 25,144,764 shares issued at December 31, 2020 and December 31, 2019, respectively

246

 

 

247

 

Treasury stock, at cost, 2,584,119 and 2,425,430 shares at December 31, 2020 and December 31, 2019, respectively

(129,886

)

 

(128,348

)

Additional paid-in capital

454,512

 

 

460,781

 

Retained earnings

214,009

 

 

237,849

 

Accumulated other comprehensive income

13,061

 

 

14,936

 

Total stockholders’ equity

551,942

 

 

585,465

 

Total liabilities and stockholders’ equity

$

1,057,476

 

 

$

1,104,271

 

HURON CONSULTING GROUP INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

Twelve Months Ended

December 31,

 

2020

 

2019

Cash flows from operating activities:

 

 

 

Net income (loss)

$

(23,840

)

 

$

41,743

 

Adjustments to reconcile net income (loss) to cash flows from operating activities:

 

 

 

Depreciation and amortization

30,222

 

 

34,405

 

Non-cash lease expense

7,763

 

 

8,397

 

Lease impairment charges

13,217

 

 

805

 

Share-based compensation

24,081

 

 

24,213

 

Amortization of debt discount and issuance costs

793

 

 

8,264

 

Goodwill impairment charges

59,816

 

 

 

Allowances for doubtful accounts

1,050

 

 

250

 

Deferred income taxes

(9,859

)

 

8,795

 

Loss on sale of business

1,603

 

 

 

Change in fair value of contingent consideration liabilities

 

 

(1,506

)

Change in fair value of preferred stock investment

(1,667

)

 

 

Other, net

(25

)

 

(789

)

Changes in operating assets and liabilities, net of acquisitions and divestiture:

 

 

 

(Increase) decrease in receivables from clients, net

33,051

 

 

(10,123

)

(Increase) decrease in unbilled services, net

18,876

 

 

(10,269

)

(Increase) decrease in current income tax receivable / payable, net

(3,662

)

 

4,442

 

(Increase) decrease in other assets

(11,972

)

 

(144

)

Increase (decrease) in accounts payable and other liabilities

(7,786

)

 

(6,884

)

Increase (decrease) in accrued payroll and related benefits

(1,169

)

 

30,339

 

Increase (decrease) in deferred revenues

6,246

 

 

282

 

Net cash provided by operating activities

136,738

 

 

132,220

 

Cash flows from investing activities:

 

 

 

Purchases of property and equipment, net

(8,125

)

 

(13,240

)

Investment in life insurance policies

(2,462

)

 

(4,703

)

Purchases of businesses

(8,701

)

 

(2,500

)

Purchases of investment securities

(13,000

)

 

(5,000

)

Capitalization of internally developed software costs

(8,272

)

 

(10,312

)

Proceeds from sale of property and equipment

25

 

 

753

 

Divestiture of business

(1,499

)

 

 

Net cash used in investing activities

(42,034

)

 

(35,002

)

Cash flows from financing activities:

 

 

 

Proceeds from exercise of stock options

1,003

 

 

1,244

 

Shares redeemed for employee tax withholdings

(7,903

)

 

(5,382

)

Share repurchases

(27,141

)

 

(12,985

)

Proceeds from bank borrowings

283,000

 

 

347,000

 

Repayments of bank borrowings

(288,574

)

 

(192,515

)

Repayment of convertible notes

 

 

(250,000

)

Payment of debt issuance costs

 

 

(1,524

)

Payments for contingent consideration liabilities

 

 

(4,674

)

Net cash used in financing activities

(39,615

)

 

(118,836

)

Effect of exchange rate changes on cash

484

 

 

115

 

Net increase (decrease) in cash and cash equivalents

55,573

 

 

(21,503

)

Cash and cash equivalents at beginning of the period

11,604

 

 

33,107

 

Cash and cash equivalents at end of the period

$

67,177

$

11,604

 

HURON CONSULTING GROUP INC.

SEGMENT OPERATING RESULTS AND OTHER OPERATING DATA

(Unaudited)

 

 

Three Months Ended

December 31,

 

Percent

Increase

(Decrease)

Segment and Consolidated Operating Results (in thousands):

 

2020

 

2019

 

Healthcare:

 

 

 

 

 

 

Revenues

 

$

85,097

 

 

 

$

103,600

 

 

 

(17.9

)

%

Operating income

 

$

24,094

 

 

 

$

31,666

 

 

 

(23.9

)

%

Segment operating income as a percentage of segment revenues

 

28.3

 

%

 

30.6

 

%

 

 

Business Advisory:

 

 

 

 

 

 

Revenues

 

$

65,938

 

 

 

$

68,906

 

 

 

(4.3

)

%

Operating income

 

$

10,740

 

 

 

$

16,698

 

 

 

(35.7

)

%

Segment operating income as a percentage of segment revenues

 

16.3

 

%

 

24.2

 

%

 

 

Education:

 

 

 

 

 

 

Revenues

 

$

47,312

 

 

 

$

59,763

 

 

 

(20.8

)

%

Operating income

 

$

5,711

 

 

 

$

12,506

 

 

 

(54.3

)

%

Segment operating income as a percentage of segment revenues

 

12.1

 

%

 

20.9

 

%

 

 

Total Company:

 

 

 

 

 

 

Revenues

 

$

198,347

 

 

 

$

232,269

 

 

 

(14.6

)

%

Reimbursable expenses

 

1,754

 

 

 

22,930

 

 

 

(92.4

)

%

Total revenues and reimbursable expenses

 

$

200,101

 

 

 

$

255,199

 

 

 

(21.6

)

%

Statements of Operations reconciliation:

 

 

 

 

 

 

Segment operating income

 

$

40,545

 

 

 

$

60,870

 

 

 

(33.4

)

%

Items not allocated at the segment level:

 

 

 

 

 

 

Other operating expenses

 

47,429

 

 

 

34,916

 

 

 

35.8

 

%

Litigation and other losses

 

 

 

 

375

 

 

 

N/M

Depreciation and amortization

 

5,770

 

 

 

7,080

 

 

 

(18.5

)

%

Total operating income (loss)

 

(12,654

)

 

 

18,499

 

 

 

N/M

Other income (expense), net

 

1,808

 

 

 

(889

)

 

 

N/M

Income (loss) from continuing operations before taxes

 

$

(10,846

)

 

 

$

17,610

 

 

 

N/M

Other Operating Data:

 

 

 

 

 

 

Number of full-time billable consultants (at period end) (1):

 

 

 

 

 

 

Healthcare

 

820

 

 

 

890

 

 

 

(7.9

)

%

Business Advisory

 

1,051

 

 

 

930

 

 

 

13.0

 

%

Education

 

737

 

 

 

756

 

 

 

(2.5

)

%

Total

 

2,608

 

 

 

2,576

 

 

 

1.2

 

%

Average number of full-time billable consultants (for the period) (1):

 

 

 

 

 

 

Healthcare

 

834

 

 

 

889

 

 

 

 

Business Advisory

 

1,028

 

 

 

941

 

 

 

 

Education

 

764

 

 

 

752

 

 

 

 

Total

 

2,626

 

 

 

2,582

 

 

 

 

HURON CONSULTING GROUP INC.

SEGMENT OPERATING RESULTS AND OTHER OPERATING DATA (CONTINUED)

(Unaudited)

 

 

Three Months Ended

December 31,

Other Operating Data (continued):

 

2020

 

2019

Full-time billable consultant utilization rate (2):

 

 

 

 

Healthcare

 

65.1

%

 

76.5

%

Business Advisory

 

71.6

%

 

71.9

%

Education

 

66.1

%

 

77.1

%

Total

 

68.0

%

 

75.0

%

Full-time billable consultant average billing rate per hour (3):

 

 

 

 

Healthcare

 

$

297

 

 

$

251

 

Business Advisory (4)

 

$

189

 

 

$

218

 

Education

 

$

179

 

 

$

197

 

Total (4)

 

$

217

 

 

$

223

 

Revenue per full-time billable consultant (in thousands):

 

 

 

 

Healthcare

 

$

79

 

 

$

84

 

Business Advisory

 

$

60

 

 

$

70

 

Education

 

$

53

 

 

$

69

 

Total

 

$

64

 

 

$

74

 

Average number of full-time equivalents (for the period) (5):

 

 

 

 

Healthcare

 

275

 

 

263

 

Business Advisory

 

40

 

 

15

 

Education

 

40

 

 

59

 

Total

 

355

 

 

337

 

Revenue per full-time equivalent (in thousands):

 

 

 

 

Healthcare

 

$

70

 

 

$

111

 

Business Advisory

 

$

94

 

 

$

187

 

Education

 

$

170

 

 

$

141

 

Total

 

$

84

 

 

$

120

 

HURON CONSULTING GROUP INC.

SEGMENT OPERATING RESULTS AND OTHER OPERATING DATA (CONTINUED)

(Unaudited)

 

 

Twelve Months Ended

December 31,

 

Percent

Increase

(Decrease)

Segment and Consolidated Operating Results (in thousands):

 

2020

 

2019

 

Healthcare:

 

 

 

 

 

 

Revenues

 

$

353,437

 

 

 

$

399,221

 

 

 

(11.5

)

%

Operating income

 

$

94,925

 

 

 

$

125,724

 

 

 

(24.5

)

%

Segment operating income as a percentage of segment revenues

 

26.9

 

%

 

31.5

 

%

 

 

Business Advisory:

 

 

 

 

 

 

Revenues

 

$

267,361

 

 

 

$

252,508

 

 

 

5.9

 

%

Operating income

 

$

48,046

 

 

 

$

49,695

 

 

 

(3.3

)

%

Segment operating income as a percentage of segment revenues

 

18.0

 

%

 

19.7

 

%

 

 

Education:

 

 

 

 

 

 

Revenues

 

$

223,329

 

 

 

$

225,028

 

 

 

(0.8

)

%

Operating income

 

$

47,503

 

 

 

$

55,741

 

 

 

(14.8

)

%

Segment operating income as a percentage of segment revenues

 

21.3

 

%

 

24.8

 

%

 

 

Total Company:

 

 

 

 

 

 

Revenues

 

$

844,127

 

 

 

$

876,757

 

 

 

(3.7

)

%

Reimbursable expenses

 

26,887

 

 

 

88,717

 

 

 

(69.7

)

%

Total revenues and reimbursable expenses

 

$

871,014

 

 

 

$

965,474

 

 

 

(9.8

)

%

Statements of Operations reconciliation:

 

 

 

 

 

 

Segment operating income

 

$

190,474

 

 

 

$

231,160

 

 

 

(17.6

)

%

Items not allocated at the segment level:

 

 

 

 

 

 

Other operating expenses

 

135,255

 

 

 

140,285

 

 

 

(3.6

)

%

Litigation and other gains

 

(150

)

 

 

(1,196

)

 

 

(87.5

)

%

Depreciation and amortization

 

24,405

 

 

 

28,365

 

 

 

(14.0

)

%

Goodwill impairment charges (6)

 

59,816

 

 

 

 

 

 

N/M

Total operating income (loss)

 

(28,852

)

 

 

63,706

 

 

 

N/M

Other expense, net

 

(5,021

)

 

 

(11,215

)

 

 

(55.2

)

%

Income (loss) from continuing operations before taxes

 

$

(33,873

)

 

 

$

52,491

 

 

 

N/M

Other Operating Data:

 

 

 

 

 

 

Number of full-time billable consultants (at period end) (1):

 

 

 

 

 

 

Healthcare

 

820

 

 

 

890

 

 

 

(7.9

)

%

Business Advisory

 

1,051

 

 

 

930

 

 

 

13.0

 

%

Education

 

737

 

 

 

756

 

 

 

(2.5

)

%

Total

 

2,608

 

 

 

2,576

 

 

 

1.2

 

%

Average number of full-time billable consultants (for the period) (1):

 

 

 

 

 

 

Healthcare

 

863

 

 

 

849

 

 

 

 

Business Advisory

 

962

 

 

 

892

 

 

 

 

Education

 

775

 

 

 

686

 

 

 

 

Total

 

2,600

 

 

 

2,427

 

 

 

 

HURON CONSULTING GROUP INC.

SEGMENT OPERATING RESULTS AND OTHER OPERATING DATA (CONTINUED)

(Unaudited)

 

 

Twelve Months Ended

December 31,

Other Operating Data (continued):

 

2020

 

2019

Full-time billable consultant utilization rate (2):

 

 

 

 

Healthcare

 

69.0

%

 

79.4

%

Business Advisory

 

72.4

%

 

72.5

%

Education

 

70.3

%

 

76.8

%

Total

 

70.7

%

 

76.1

%

Full-time billable consultant average billing rate per hour (3):

 

 

 

 

Healthcare

 

$

246

 

 

$

231

 

Business Advisory (4)

 

$

195

 

 

$

201

 

Education

 

$

187

 

 

$

199

 

Total (4)

 

$

208

 

 

$

211

 

Revenue per full-time billable consultant (in thousands):

 

 

 

 

Healthcare

 

$

295

 

 

$

331

 

Business Advisory

 

$

264

 

 

$

273

 

Education

 

$

247

 

 

$

285

 

Total

 

$

269

 

 

$

297

 

Average number of full-time equivalents (for the period) (5):

 

 

 

 

Healthcare

 

278

 

 

244

 

Business Advisory

 

30

 

 

14

 

Education

 

52

 

 

47

 

Total

 

360

 

 

305

 

Revenue per full-time equivalent (in thousands):

 

 

 

 

Healthcare

 

$

356

 

 

$

485

 

Business Advisory

 

$

455

 

 

$

655

 

Education

 

$

618

 

 

$

617

 

Total

 

$

402

 

 

$

513

 

(1)

Consists of full-time professionals who provide consulting services and generate revenues based on the number of hours worked.

(2)

Utilization rate for full-time billable consultants is calculated by dividing the number of hours full-time billable consultants worked on client assignments during a period by the total available working hours for these consultants during the same period, assuming a forty-hour work week, less paid holidays and vacation days.

(3)

Average billing rate per hour for full-time billable consultants is calculated by dividing revenues for a period by the number of hours worked on client assignments during the same period.

(4)

The Business Advisory segment includes operations of Huron Eurasia India. Absent the impact of Huron Eurasia India, the average billing rate per hour for the Business Advisory segment would have been $203 and $254 for the three months ended December 31, 2020 and 2019, respectively; and $213 and $228 for the year ended December 31, 2020 and 2019, respectively.

Absent the impact of Huron Eurasia India, Huron’s consolidated average billing rate per hour would have been $223 and $235 for the three months ended December 31, 2020 and 2019, respectively; and $215 and $220 for the year ended December 31, 2020 and 2019, respectively.

(5)

Consists of coaches and their support staff within the Culture and Organizational Excellence solution, consultants who work variable schedules as needed by clients, employees who provide managed services in our Healthcare segment, and full-time employees who provide software support and maintenance services to clients.

(6)

The non-cash goodwill impairment charges are not allocated at the segment level because the underlying goodwill asset is reflective of our corporate investment in the segments. We do not include the impact of goodwill impairment charges in our evaluation of segment performance.

N/M – Not Meaningful

HURON CONSULTING GROUP INC.

RECONCILIATION OF NET INCOME (LOSS) FROM CONTINUING OPERATIONS

TO ADJUSTED EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION (7)

(In thousands)

(Unaudited)

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

 

2020

 

2019

 

2020

 

2019

Revenues

$

198,347

 

 

 

$

232,269

 

 

 

$

844,127

 

 

 

$

876,757

 

 

Net income (loss) from continuing operations

$

(6,104

)

 

 

$

14,354

 

 

 

$

(23,718

)

 

 

$

41,979

 

 

Add back:

 

 

 

 

 

 

 

Income tax expense (benefit)

(4,742

)

 

 

3,256

 

 

 

(10,155

)

 

 

10,512

 

 

Interest expense, net of interest income

1,776

 

 

 

2,492

 

 

 

9,292

 

 

 

15,648

 

 

Depreciation and amortization

7,156

 

 

 

9,005

 

 

 

29,644

 

 

 

33,740

 

 

Earnings (loss) before interest, taxes, depreciation and amortization (EBITDA) (7)

(1,914

)

 

 

29,107

 

 

 

5,063

 

 

 

101,879

 

 

Add back:

 

 

 

 

 

 

 

Restructuring and other charges (gains)

18,748

 

 

 

(301

)

 

 

21,374

 

 

 

1,855

 

 

Litigation and other losses (gains), net

 

 

 

375

 

 

 

(150

)

 

 

(1,196

)

 

Transaction-related expenses

695

 

 

 

67

 

 

 

1,132

 

 

 

2,680

 

 

Goodwill impairment charges

 

 

 

 

 

 

59,816

 

 

 

 

 

Unrealized gain on preferred stock investment

(1,667

)

 

 

 

 

 

(1,667

)

 

 

 

 

Losses on sales of businesses

1,501

 

 

 

 

 

 

1,603

 

 

 

 

 

Foreign currency transaction losses (gains), net

(276

)

 

 

124

 

 

 

(31

)

 

 

160

 

 

Adjusted EBITDA (7)

$

17,087

 

 

 

$

29,372

 

 

 

$

87,140

 

 

 

$

105,378

 

 

Adjusted EBITDA as a percentage of revenues (7)

8.6

 

%

 

12.6

 

%

 

10.3

 

%

 

12.0

 

%

HURON CONSULTING GROUP INC.

RECONCILIATION OF NET INCOME (LOSS) FROM CONTINUING OPERATIONS

TO ADJUSTED NET INCOME FROM CONTINUING OPERATIONS (7)

(In thousands, except per share amounts)

(Unaudited)

 

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

 

2020

 

2019

 

2020

 

2019

Net income (loss) from continuing operations

$

(6,104

)

 

$

14,354

 

 

$

(23,718

)

 

$

41,979

 

Weighted average shares – diluted

21,903

 

 

22,676

 

 

21,882

 

 

22,507

 

Diluted earnings (loss) per share from continuing operations

$

(0.28

)

 

$

0.63

 

 

$

(1.08

)

 

$

1.87

 

Add back:

 

 

 

 

 

 

 

Amortization of intangible assets

3,138

 

 

4,757

 

 

12,696

 

 

17,793

 

Restructuring and other charges (gains)

18,748

 

 

(301

)

 

21,374

 

 

1,855

 

Litigation and other losses (gains), net

 

 

375

 

 

(150

)

 

(1,196

)

Transaction-related expenses

695

 

 

67

 

 

1,132

 

 

2,680

 

Goodwill impairment charges

 

 

 

 

59,816

 

 

 

Non-cash interest on convertible notes

 

 

 

 

 

 

6,436

 

Unrealized gain on preferred stock investment

(1,667

)

 

 

 

(1,667

)

 

 

Losses on sales of businesses

1,501

 

 

 

 

1,603

 

 

 

Tax effect of adjustments

(6,158

)

 

(1,291

)

 

(23,199

)

 

(7,200

)

Tax benefit related to “check-the-box” election

 

 

 

 

 

 

(736

)

Total adjustments, net of tax

16,257

 

 

3,607

 

 

71,605

 

 

19,632

 

Adjusted net income from continuing operations (7)

$

10,153

 

 

$

17,961

 

 

$

47,887

 

 

$

61,611

 

Adjusted weighted average shares – diluted (8)

22,323

 

 

22,676

 

 

22,299

 

 

22,507

 

Adjusted diluted earnings per share from continuing operations (7)

$

0.45

 

 

$

0.79

 

 

$

2.15

 

 

$

2.74

 

(7)

In evaluating the company’s financial performance and outlook, management uses earnings (loss) before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted EBITDA as a percentage of revenues, adjusted net income from continuing operations, and adjusted diluted earnings per share from continuing operations, which are non-GAAP measures. Management uses these non-GAAP financial measures to gain an understanding of the company’s comparative operating performance (when comparing such results with previous periods or forecasts). These non-GAAP financial measures are used by management in their financial and operating decision making because management believes they reflect the company’s ongoing business in a manner that allows for meaningful period-to-period comparisons. Management also uses these non-GAAP financial measures when publicly providing the company’s business outlook, for internal management purposes, and as a basis for evaluating potential acquisitions and dispositions. Management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating Huron’s current operating performance and future prospects in the same manner as management does, if they so choose, and in comparing in a consistent manner Huron’s current financial results with Huron’s past financial results. Investors should recognize that these non-GAAP measures might not be comparable to similarly titled measures of other companies. These measures should be considered in addition to, and not as a substitute for or superior to, any measure of performance, cash flows or liquidity prepared in accordance with accounting principles generally accepted in the United States.

(8)

As the company reported a net loss for the three and twelve months ended December 31, 2020, GAAP diluted weighted average shares outstanding equals the basic weighted average shares outstanding for that period. The non-GAAP adjustments resulted in adjusted net income from continuing operations for the three and twelve months ended December 31, 2020. Therefore, dilutive common stock equivalents have been included in the calculation of adjusted diluted weighted average shares outstanding.

 

MEDIA CONTACT

Allie Bovis

[email protected]

INVESTOR CONTACT

John D. Kelly

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Professional Services Consulting

MEDIA:

Logo
Logo

ClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the closing of its previously disclosed public offering of common stock. The total number of shares of common stock sold was 2,127,660, composed of 1,850,140 shares of common stock initially offered at a public offering price of $23.50 per share and an additional 277,520 shares of common stock sold pursuant to the exercise of the underwriters’ option to purchase additional shares at the price of $22.09 per share. The net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $46.8 million. The Company will use the net proceeds from the offering to fund product development and research and development activities and the remainder for working capital and general corporate purposes.

“We are very pleased with the result and closing of this recent stock offering,” commented Joe Burnett, the Company’s President and Chief Executive Officer. “Our team has done a tremendous job accumulating the necessary partnerships we need across our portfolio of Neuro-based Biologics, Navigation and Therapy, the same way you would lay out all of your chess pieces before starting the match. The next two years is about putting all of those chess pieces in motion and executing against our strategic plan. Adding this new capital to our balance sheet increases our level of control and our capability to do just that.”

B. Riley Securities acted as book-running manager and Lake Street Capital Markets, LLC acted as co-manager for the offering.

The shares were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-252346) filed with the Securities and Exchange Commission (the “SEC”). An electronic copy of the final prospectus supplement, dated February 18, 2021, and accompanying prospectus are available on the SEC website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained by visiting the SEC’s website, or from B. Riley Securities, Inc., Attention: Prospectus Department, 1300 North 17th Street, Suite 1300, Arlington, Virginia 22209, or by telephone at 703-312-9580 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States, Canada, and Europe. The Company’s SmartFlow® cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering, and those factors described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and the Company’s Quarterly Reports on Form 10-Q for the three months ended March 31, 2020, June 30, 2020, and September 30, 2020, all of which have been filed with the Securities and Exchange Commission, and the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2021.



Contact:

Danilo D’Alessandro, Chief Financial Officer
(949) 900-6833
[email protected]

Jacqueline Keller, Vice President, Marketing
(949) 900-6833
[email protected]

ViacomCBS CEO Bob Bakish to Participate in the Virtual Morgan Stanley Technology, Media and Telecom Conference

ViacomCBS CEO Bob Bakish to Participate in the Virtual Morgan Stanley Technology, Media and Telecom Conference

NEW YORK–(BUSINESS WIRE)–
ViacomCBS Inc. (NASDAQ: VIAC; VIACA) today announced that Bob Bakish, President and Chief Executive Officer, will participate in a question and answer session during the virtual Morgan Stanley Technology, Media and Telecom Conference on Tuesday, March 2, 2021 at 7:45am ET.

A live audio webcast of the call will be available on the Investors homepage of ViacomCBS’ website (ir.viacomcbs.com). A replay of the audio webcast will be available in the Events, Webcasts & Annual Meetings section of ViacomCBS’ Investors website.

About ViacomCBS

ViacomCBS (NASDAQ: VIAC; VIACA) is a leading global media and entertainment company that creates premium content and experiences for audiences worldwide. Driven by iconic consumer brands, its portfolio includes CBS, Showtime Networks, Paramount Pictures, Nickelodeon, MTV, Comedy Central, BET, CBS All Access, Pluto TV and Simon & Schuster, among others. The company delivers the largest share of the U.S. television audience and boasts one of the industry’s most important and extensive libraries of TV and film titles. In addition to offering innovative streaming services and digital video products, ViacomCBS provides powerful capabilities in production, distribution and advertising solutions for partners on five continents.

For more information about ViacomCBS, please visit www.viacomcbs.com and follow @ViacomCBS on social platforms.

VIAC-IR

Press:

Peter Collins

Vice President, Corporate Communications

(917) 826-4182

[email protected]

Justin Blaber

Senior Director, Corporate Communications

(646) 823-6616

[email protected]

Pranita Sookai

Director, Corporate Communications

(718) 316-2182

[email protected]

Investors:

Anthony DiClemente

Executive Vice President, Investor Relations

(917) 796-4647

[email protected]

Jaime Morris

Vice President, Investor Relations

(646) 824-5450

[email protected]

Robert Amparo

Manager, Investor Relations

(347) 223-1682

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Advertising Entertainment Communications Film & Motion Pictures TV and Radio General Entertainment Publishing

MEDIA:

Logo
Logo

Trupanion Announces Participation at the Raymond James 42nd Annual Institutional Investors Conference

SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP) announced today that the Company will participate in the Raymond James 42nd Annual Institutional Investors Conference on Tuesday, March 2, 2021. Darryl Rawlings, Trupanion’s founder and Chief Executive Officer, is scheduled to present virtually at 3:50 pm ET and will participate in virtual meetings with investors throughout the day.

The presentation will be webcast live and can be accessed on Trupanion’s Investor Relations website at http://investors.trupanion.com.

About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States and Canada. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet’s recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. Trupanion is listed on NASDAQ under the symbol “TRUP”. The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. For more information, please visit Trupanion.com.

Investors:
Laura Bainbridge, Head of Corporate Communications
[email protected]



Arlo Reports Fourth Quarter 2020 and Full Year 2020 Results

Arlo Reports Fourth Quarter 2020 and Full Year 2020 Results

Exceeded High-End of EPS Guidance for the Quarter

Delivered Highest Gross Margin in Nine Quarters

Fourth Quarter Service Revenue Growth of 72.1% Year Over Year for a Sixth Consecutive Quarterly Record

89.1% Paid Account Growth Year Over Year

Ended Year with Cash, Cash Equivalents and Short-term Investments Balance at $206.1 million with No Debt

SAN JOSE, Calif.–(BUSINESS WIRE)–
Arlo Technologies, Inc. (NYSE: ARLO), a leading internet-connected security camera brand, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.

Financial Highlights (1)

  • Fourth quarter revenue of $114.8 million, a decrease of 6.2% year over year.
  • Fourth quarter GAAP gross profit of $24.5 million, an increase of 79.0% year over year; non-GAAP gross profit of $25.7 million, an increase of 73.0% year over year.
  • Fourth quarter GAAP gross margin of 21.4%; non-GAAP gross margin of 22.4%.
  • Fourth quarter GAAP net loss per diluted share of $(0.19); non-GAAP net loss per diluted share of $(0.08).
  • 2020 revenue of $357.2 million, a decrease of 3.5% compared to prior year.
  • 2020 GAAP gross profit of $55.4 million, an increase of 54.7% compared to prior year; non-GAAP gross profit of $59.7 million, an increase of 51.5% compared to prior year.
  • 2020 GAAP gross margin of 15.5%; non-GAAP gross margin of 16.7%.
  • 2020 GAAP net loss per diluted share of $(1.30); non-GAAP net loss per diluted share of $(0.82).
  • Cash, cash equivalents and short-term investments of $206.1 million and no debt at the end of Q4.

“2020 was an unprecedented year and I am exceedingly proud of our team’s perseverance and determination in the face of the ongoing pandemic. In Q4, revenue grew 4.2% sequentially to $114.8 million to come in at the top end of our guidance. The strength of our new business model, a free, 90-day trial of Arlo Smart, continues to accelerate the momentum of our paid account growth and the fourth quarter was another great example. We closed out the year with an 89.1% year over year paid account growth and saw service gross margin improve 10 percentage points year over year. Our unwavering commitment to operational efficiency drove a significant year over year decrease in operating expenses and led us to solidly outperform the high end of our guidance for EPS. We also kept our focus on robust innovation and launched two new products in the fourth quarter,” said Matthew McRae, Chief Executive Officer of Arlo Technologies. “In 2020 we laid a solid foundation to become a more profitable and predictable business with strong progress with our Verisure partnership and by refreshing our entire product line up to drive paid account growth with our new business model. Looking forward, we expect to roughly triple our paid account additions in 2021 and reach one million paid accounts by this time next year. We believe Arlo is on solid financial and operational footing and look forward to continuing our execution in 2021.”

 

Three Months Ended

 

Twelve Months Ended

 

December 31,

2020

 

September 27,

2020

 

December 31,

2019

 

December 31,

2020

 

December 31,

2019

 

(in thousands, except percentage and per share data)

Revenue

$

114,836

 

 

$

110,236

 

 

$

122,413

 

 

$

357,154

 

 

$

370,007

 

GAAP Gross Margin

21.4

%

 

19.4

%

 

11.2

%

 

15.5

%

 

9.7

%

Non-GAAP Gross Margin (1)

22.4

%

 

20.6

%

 

12.2

%

 

16.7

%

 

10.6

%

GAAP Net Income (Loss) per Diluted Share

$

(0.19

)

 

$

(0.22

)

 

$

0.26

 

 

$

(1.30

)

 

$

(1.14

)

Non-GAAP Net Income (Loss) per Diluted Share (1)

$

(0.08

)

 

$

(0.10

)

 

$

(0.26

)

 

$

(0.82

)

 

$

(1.42

)

_________________________

(1) Reconciliation of financial measures computed on a GAAP basis to financial measures computed on a non-GAAP basis are provided at the end of this press release.

Business Highlights

  • Full year service revenue of $72.3 million, for growth of 54.6% year over year.
  • Service revenue of $21.6 million for Q4, for growth of 72.1% year over year.
  • Added a record 79,000 paid accounts in Q4, a sequential increase of 22.2% over Q3, and a year over year increase of 89.1%.
  • Announced the all new Arlo Touchless Video Doorbell, which builds on the award-winning features of the Video Doorbell. Utilizing our precise Proximity Sensing Technology, the Touchless Video Doorbell can automatically detect a visitor’s approach and “press” the doorbell, alerting both homeowner and visitor without the need for physical contact with the device. The Touchless Video Doorbell also includes a three-month subscription to Arlo Smart.
  • Expanded the Arlo Essential product family with the addition of the Essential Indoor Camera, which sports all of the Essential’s great features while incorporating new design elements for optimal indoor use. The Essential Indoor Camera features a stand mount and a power cord for easy and flexible indoor placement, along with a built-in motorized shutter to quickly and easily turn the camera on and off. This Essential Indoor Camera also includes a three-month subscription to Arlo Smart.
  • Partnered with Calix and its broad network of Communications Service Providers to seamlessly offer Arlo products and services as part of a homeowner’s overall managed WiFi experience.
  • The newly announced Essential Indoor Camera and Touchless Video Doorbell were named CES 2021 Innovation Award Honorees, making this the third consecutive year of recognition for Arlo products by the Consumer Technology Association.

First Quarter 2021 Business Outlook (2)

  • Revenue of $70.0 million to $80.0 million.
  • GAAP net loss per diluted share of $(0.35) to $(0.29), and non-GAAP net loss per diluted share of $(0.23) to $(0.17).

A reconciliation of our business outlook on a GAAP and non-GAAP basis is provided in the following table:

 

Three Months Ending March 28, 2021

 

Revenue

 

Net Loss per Diluted Share

 

(in millions, except per share data)

GAAP

$70.0 – $80.0

 

$(0.35) – $(0.29)

Estimated adjustments for (2):

 

 

 

Stock-based compensation expense

 

0.12

Tax effects of non-GAAP adjustments

 

Non-GAAP

$70.0 – $80.0

 

$(0.23) – $(0.17)

_________________________

(2) Business outlook does not include estimates for any currently unknown income and expense items which, by their nature, could arise late in a quarter, including: litigation reserves, net; acquisition-related charges; impairment charges; discrete tax benefits or detriments relating to tax windfalls or shortfalls from equity awards; and any additional impacts relating to the implementation of U.S. tax reform. New material income and expense items such as these could have a significant effect on our guidance and future results.

Investor Conference Call / Webcast Details

Arlo will review the fourth quarter of 2020 results and discuss management’s expectations for the first quarter of 2021 today, Tuesday, February 23, 2021 at 5:00 p.m. ET (2:00 p.m. PT). The toll free dial-in number for the live audio call is (866) 393-4306. The international dial-in number for the live audio call is (734) 385-2616. The conference ID for the call is 8394616. A live webcast of the conference call will be available on Arlo’s Investor Relations website at https://investor.arlo.com. A replay of the call will be available via the web at https://investor.arlo.com.

About Arlo Technologies, Inc.

Arlo (NYSE: ARLO) is the award-winning, industry leader that is transforming the way people experience the connected lifestyle. Arlo’s deep expertise in product design, wireless connectivity, cloud infrastructure and cutting-edge AI capabilities focuses on delivering a seamless, smart home experience for Arlo users that is easy to setup and interact with every day. Arlo’s cloud-based platform provides users with visibility, insight and a powerful means to help protect and connect in real-time with the people and things that matter most, from any location with a Wi-Fi or a cellular connection. To date, Arlo has launched several categories of award-winning smart connected devices, including wire-free smart Wi-Fi and LTE-enabled cameras, advanced baby monitors and smart security lights.

© 2019 Arlo Technologies, Inc., Arlo and the Arlo logo are trademarks and/or registered trademarks of Arlo Technologies, Inc. and/or certain of its affiliates in the United States and/or other countries. Other brand and product names are for identification purposes only and may be trademarks or registered trademarks of their respective holder(s). The information contained herein is subject to change without notice. Arlo shall not be liable for technical or editorial errors or omissions contained herein. All rights reserved.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words are used to identify such forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. The forward-looking statements represent Arlo Technologies, Inc.’s expectations or beliefs concerning future events based on information available at the time such statements were made and include statements regarding: Arlo’s future operating performance and financial condition, expected revenue, GAAP and non-GAAP gross margins, operating margins, and tax expense; expectations regarding market expansion and future growth; plans to invest in product innovation; Arlo’s future product offerings; and the quote from Arlo’s Chief Executive Officer. These statements are based on management’s current expectations and are subject to certain risks and uncertainties, including the following: future demand for the Company’s products may be lower than anticipated; consumers may choose not to adopt the Company’s new product offerings or adopt competing products; product performance may be adversely affected by real world operating conditions; the Company may be unsuccessful or experience delays in manufacturing and distributing its new and existing products; telecommunications service providers may choose to slow their deployment of the Company’s products or utilize competing products; the Company may be unable to collect receivables as they become due; the Company may fail to manage costs, including the cost of developing new products and manufacturing and distribution of its existing offerings; the Company may incur additional costs and charges associated with the transactions contemplated by the Verisure partnership; the Company may not receive the minimum commitment amounts from Verisure; the COVID-19 pandemic could have an adverse impact on the Company’s business, operations and the markets and communities in which Arlo and its partners and customers operate; the Company may fail to successfully continue to effect operating expense savings; changes in the level of Arlo’s cash resources and the Company’s planned usage of such resources; changes in the Company’s stock price and developments in the business that could increase the Company’s cash needs; fluctuations in foreign exchange rates; the actions and financial health of the Company’s customers; the anticipated financial capacity under Arlo’s revolving credit line may not be available when expected, or at all; and the Company may not be able to carry out its restructuring plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Therefore, actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Further information on potential risk factors that could affect Arlo and its business are detailed in the Company’s periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Part II – Item 1A. Risk Factors,” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2020, filed with the Securities and Exchange Commission on November 5, 2020 and other periodic filings with the Securities and Exchange Commission. Given these circumstances, you should not place undue reliance on these forward-looking statements. Arlo undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Non-GAAP Financial Information:

To supplement our unaudited selected financial data presented on a basis consistent with U.S. Generally Accepted Accounting Principles (“GAAP”), we disclose certain non-GAAP financial measures that exclude certain charges, including non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development, non-GAAP sales and marketing, non-GAAP general and administrative, non-GAAP total operating expenses, non-GAAP operating income (loss), non-GAAP operating margin, non-GAAP provision for income taxes, non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share. These supplemental measures exclude adjustments for separation expense, stock-based compensation expense, amortization of intangibles, activist shareholder response costs, restructuring and other charges, strategic initiative and transaction expenses, gain on sale of business, litigation reserves, and the related tax effects. These non-GAAP measures are not in accordance with or an alternative for GAAP, and may be different from similarly-titled non-GAAP measures used by other companies. We believe that these non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the most directly comparable GAAP measures. We compensate for the limitations of non-GAAP financial measures by relying upon GAAP results to gain a complete picture of our performance.

In calculating non-GAAP financial measures, we exclude certain items to facilitate a review of the comparability of our operating performance on a period-to-period basis because such items are not, in our view, related to our ongoing operational performance. We use non-GAAP measures to evaluate the operating performance of our business, for comparison with forecasts and strategic plans, and for benchmarking performance externally against competitors. In addition, management’s incentive compensation is determined using certain non-GAAP measures. Since we find these measures to be useful, we believe that investors benefit from seeing results “through the eyes” of management in addition to seeing GAAP results. We believe that these non-GAAP measures, when read in conjunction with our GAAP measures, provide useful information to investors by offering:

– the ability to make more meaningful period-to-period comparisons of our on-going operating results;

– the ability to better identify trends in our underlying business and perform related trend analyses;

– a better understanding of how management plans and measures our underlying business; and

– an easier way to compare our operating results against analyst financial models and operating results of competitors that supplement their GAAP results with non-GAAP financial measures.

The following are explanations of the adjustments that we incorporate into non-GAAP measures, as well as the reasons for excluding them in the reconciliations of these non-GAAP financial measures:

Separation expense consists of expenses that are related to the separation of our business from NETGEAR. These consist primarily of third-party consulting fees, legal fees, IT costs, employee bonuses for services related to the separation, and other one-time expenses incurred to complete the separation. We consider our operating results without these charges when evaluating our ongoing performance and forecasting our earnings trends, and therefore exclude such charges when presenting non-GAAP financial measures. We believe that the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of our competitors.

Stock-based compensation expense consists of non-cash charges for the estimated fair value of stock options, performance-based stock options, restricted stock units and shares under the employee stock purchase plan granted to employees. We believe that the exclusion of these charges provides for more accurate comparisons of our operating results to peer companies due to the varying available valuation methodologies, subjective assumptions and the variety of award types. In addition, we believe it is useful to investors to understand the specific impact stock-based compensation expense has on our operating results.

Amortization of intangibles consists primarily of non-cash charges that can be impacted by, among other things, the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing performance and forecasting our earnings trends, and therefore exclude such charges when presenting non-GAAP financial measures. We believe that the assessment of our operations excluding these costs is relevant to an assessment of our internal operations and comparisons to our prior and future periods and to the performance of our competitors.

Activist shareholder response costs primarily consist of legal fees and third-party consulting costs incurred. We consider our operating results without these charges when evaluating our ongoing performance and forecasting our earnings trends, and therefore exclude such charges when presenting non-GAAP financial measures. We believe that the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of our competitors.

Strategic initiative and transaction expenses consist of legal fees associated with the strategic review of the Company and legal fees, accounting fees and other one-time costs incurred to complete the Verisure transaction. We consider our operating results without these charges when evaluating our ongoing performance and forecasting our earnings trends, and therefore exclude such charges when presenting non-GAAP financial measures. We believe that the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of our competitors.

Gain on sale of business represents gain from sale of the Company’s commercial operations in Europe. We consider our operating results without this gain when evaluating our ongoing performance and forecasting our earnings trends, and therefore exclude such gain when presenting non-GAAP financial measures. We believe that the assessment of our operations excluding the gain is relevant to our assessment of internal operations and comparisons to the performance of our competitors.

Other items are the result of either unique or unplanned events, including, when applicable: restructuring and other charges and litigation reserves, net. It is difficult to predict the occurrence or estimate the amount or timing of these items in advance. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our on-going operations with prior and future periods. The amounts result from events that often arise from unforeseen circumstances, which often occur outside of the ordinary course of continuing operations. Therefore, the amounts do not accurately reflect the underlying performance of our continuing business operations for the period in which they are incurred.

Tax effects consist of the various above adjustments that we incorporate into non-GAAP measures in order to provide a more meaningful measure on non-GAAP net income. We also believe providing financial information with and without the income tax effects relating to our non-GAAP financial measures provides our management and users of the financial statements with better clarity regarding the on-going performance of our business.

Source: Arlo-F

ARLO TECHNOLOGIES, INC.

 

CONSOLIDATED BALANCE SHEETS

 

 

As of

 

December 31,

2020

 

December 31,

2019

 

(In thousands, except share and per share data)

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

186,127

 

 

$

236,680

 

Short-term investments (amortized cost of $19,996 and $19,967)

19,997

 

 

19,990

 

Accounts receivable, net (net of allowance for credit losses of $519 and $609)

77,643

 

 

127,317

 

Inventories

64,705

 

 

68,624

 

Prepaid expenses and other current assets

8,076

 

 

16,958

 

Total current assets

356,548

 

 

469,569

 

Property and equipment, net

15,821

 

 

21,352

 

Operating lease right-of-use assets, net

23,998

 

 

31,300

 

Intangibles, net

 

 

1,306

 

Goodwill

11,038

 

 

11,038

 

Restricted cash

4,164

 

 

4,139

 

Other non-current assets

2,399

 

 

4,008

 

Total assets

$

413,968

 

 

$

542,712

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

62,171

 

 

$

111,650

 

Deferred revenue

53,142

 

 

50,362

 

Accrued liabilities

121,766

 

 

127,400

 

Income tax payable

267

 

 

4,489

 

Total current liabilities

237,346

 

 

293,901

 

Non-current deferred revenue

16,563

 

 

15,736

 

Non-current operating lease liabilities

25,029

 

 

29,001

 

Non-current income taxes payable

104

 

 

92

 

Other non-current liabilities

1,159

 

 

606

 

Total liabilities

280,201

 

 

339,336

 

Stockholders’ Equity:

 

 

 

Preferred stock: $0.001 par value; 50,000,000 shares authorized; none issued or outstanding

 

 

 

Common stock: : $0.001 par value; 500,000,000 shares authorized; shares issued and outstanding: 79,336,242 at December 31, 2020 and 75,785,952 at December 31, 2019

79

 

 

76

 

Additional paid-in capital

366,455

 

 

334,821

 

Accumulated other comprehensive income

3

 

 

(2

)

Accumulated deficit

(232,770

)

 

(131,519

)

Total stockholders’ equity

133,767

 

 

203,376

 

Total liabilities and stockholders’ equity

$

413,968

 

 

$

542,712

 

ARLO TECHNOLOGIES, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

Three Months Ended

 

Twelve Months Ended

 

December 31,

2020

 

September 27,

2020

 

December 31,

2019

 

December 31,

2020

 

December 31,

2019

 

(in thousands, except percentage and per share data)

Revenue:

 

 

 

 

 

 

 

 

 

Products

$

93,271

 

 

$

91,271

 

 

$

109,883

 

 

$

284,868

 

 

$

323,242

 

Services

21,565

 

 

18,965

 

 

12,530

 

 

72,286

 

 

46,765

 

Total revenue

114,836

 

 

110,236

 

 

122,413

 

 

357,154

 

 

370,007

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

Products

81,424

 

 

79,107

 

 

100,470

 

 

263,905

 

 

307,348

 

Services

8,874

 

 

9,720

 

 

8,237

 

 

37,860

 

 

26,855

 

Total cost of revenue

90,298

 

 

88,827

 

 

108,707

 

 

301,765

 

 

334,203

 

Gross profit

24,538

 

 

21,409

 

 

13,706

 

 

55,389

 

 

35,804

 

Gross margin

21.4

%

 

19.4

%

 

11.2

%

 

15.5

%

 

9.7

%

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

15,266

 

 

15,436

 

 

16,928

 

 

60,137

 

 

69,384

 

Sales and marketing

13,593

 

 

12,720

 

 

14,596

 

 

49,064

 

 

56,985

 

General and administrative

11,338

 

 

11,137

 

 

15,112

 

 

51,096

 

 

47,624

 

Separation expense

10

 

 

77

 

 

153

 

 

248

 

 

1,913

 

Gain on sale of business

 

 

 

 

(54,881

)

 

(292

)

 

(54,881

)

Total operating expenses

40,207

 

 

39,370

 

 

(8,092

)

 

160,253

 

 

121,025

 

Income (loss) from operations

(15,669

)

 

(17,961

)

 

21,798

 

 

(104,864

)

 

(85,221

)

Operating margin

(13.6

)%

 

(16.3

)%

 

17.8

%

 

(29.4

)%

 

(23.0

)%

Interest income

42

 

 

74

 

 

567

 

 

802

 

 

2,737

 

Other income (expense), net

599

 

 

543

 

 

775

 

 

3,436

 

 

913

 

Income (loss) before income taxes

(15,028

)

 

(17,344

)

 

23,140

 

 

(100,626

)

 

(81,571

)

Provision for income taxes

182

 

 

115

 

 

3,525

 

 

625

 

 

4,380

 

Net income (loss)

$

(15,210

)

 

$

(17,459

)

 

$

19,615

 

 

$

(101,251

)

 

$

(85,951

)

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

$

(0.19

)

 

$

(0.22

)

 

$

0.26

 

 

$

(1.30

)

 

$

(1.14

)

Diluted

$

(0.19

)

 

$

(0.22

)

 

$

0.26

 

 

$

(1.30

)

 

$

(1.14

)

Weighted average shares used to compute net income (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

79,164

 

 

78,662

 

 

75,805

 

 

78,084

 

 

75,074

 

Diluted

79,164

 

 

78,662

 

 

76,090

 

 

78,084

 

 

75,074

 

ARLO TECHNOLOGIES, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

Twelve Months Ended

 

December 31,

2020

 

December 31,

2019

 

(In thousands)

Cash flows from operating activities:

 

 

 

Net loss

$

(101,251

)

 

$

(85,951

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

10,206

 

 

10,681

 

Stock-based compensation expense

35,247

 

 

22,894

 

Allowance for (release of) credit losses and inventory reserves

964

 

 

(2,921

)

Gain on sale of business

(292

)

 

(54,881

)

Deferred income taxes

50

 

 

(210

)

Premium amortization (discount accretion) on investments, net

54

 

 

(461

)

Changes in assets and liabilities:

 

 

 

Accounts receivable, net

49,765

 

 

38,247

 

Inventories

2,862

 

 

53,604

 

Prepaid expenses and other assets

10,441

 

 

11,525

 

Accounts payable

(49,282

)

 

28,791

 

Deferred revenue

3,607

 

 

22,567

 

Accrued and other liabilities

(8,901

)

 

(34,714

)

Net cash provided by (used in) operating activities

(46,530

)

 

9,171

 

Cash flows from investing activities:

 

 

 

Purchases of property and equipment

(3,892

)

 

(6,664

)

Proceeds from sale of business

 

 

52,694

 

Purchases of short-term investments

(50,083

)

 

(29,768

)

Maturities of short-term investments

50,000

 

 

60,000

 

Net cash provided by (used in) investing activities

(3,975

)

 

76,262

 

Cash flows from financing activities:

 

 

 

Proceeds related to employee benefit plans

4,755

 

 

1,837

 

Restricted stock unit withholdings

(4,778

)

 

(1,875

)

Net cash used in financing activities

(23

)

 

(38

)

Net increase (decrease) in cash and cash equivalents and restricted cash

(50,528

)

 

85,395

 

Cash and cash equivalents and restricted cash, at beginning of period

240,819

 

 

155,424

 

Cash and cash equivalents and restricted cash, at end of period

$

190,291

 

 

$

240,819

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

Purchases of property and equipment included in accounts payable and accrued liabilities

$

564

 

 

$

1,086

 

De-recognition of build-to-suit assets and liabilities

$

 

 

$

(21,610

)

Supplemental cash flow information:

 

 

 

Cash paid for income taxes

$

5,614

 

 

$

960

 

ARLO TECHNOLOGIES, INC.

 

RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES

 

STATEMENT OF OPERATIONS DATA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

December 31,

2020

 

September 27,

2020

 

December 31,

2019

 

December 31,

2020

 

December 31,

2019

 

(in thousands, except percentage data)

GAAP gross profit:

 

 

 

 

 

 

 

 

 

Products

$

11,847

 

 

$

12,164

 

 

$

9,413

 

 

$

20,963

 

 

$

15,894

 

Services

12,691

 

 

9,245

 

 

4,293

 

 

34,426

 

 

19,910

 

Total GAAP gross profit

24,538

 

 

21,409

 

 

13,706

 

 

55,389

 

 

35,804

 

GAAP gross margin:

 

 

 

 

 

 

 

 

 

Products

12.7

%

 

13.3

%

 

8.6

%

 

7.4

%

 

4.9

%

Services

58.9

%

 

48.8

%

 

34.3

%

 

47.6

%

 

42.6

%

Total GAAP gross margin

21.4

%

 

19.4

%

 

11.2

%

 

15.5

%

 

9.7

%

Stock-based compensation expense

955

 

 

942

 

 

727

 

 

2,962

 

 

2,013

 

Amortization of intangibles

237

 

 

356

 

 

373

 

 

1,306

 

 

1,517

 

Restructuring and other charges

 

 

 

 

69

 

 

23

 

 

69

 

Non-GAAP gross profit:

 

 

 

 

 

 

 

 

 

Products

13,039

 

 

13,462

 

 

10,582

 

 

25,254

 

 

19,493

 

Services

12,691

 

 

9,245

 

 

4,293

 

 

34,426

 

 

19,910

 

Total Non-GAAP gross profit

$

25,730

 

 

$

22,707

 

 

$

14,875

 

 

$

59,680

 

 

$

39,403

 

Non-GAAP gross margin:

 

 

 

 

 

 

 

 

 

Products

14.0

%

 

14.7

%

 

9.6

%

 

8.9

%

 

6.0

%

Services

58.9

%

 

48.8

%

 

34.3

%

 

47.6

%

 

42.6

%

Total Non-GAAP gross margin

22.4

%

 

20.6

%

 

12.2

%

 

16.7

%

 

10.6

%

 

 

 

 

 

 

 

 

 

 

GAAP research and development

$

15,266

 

 

$

15,436

 

 

$

16,928

 

 

$

60,137

 

 

$

69,384

 

Stock-based compensation expense

(2,795

)

 

(2,870

)

 

(2,367

)

 

(9,054

)

 

(6,868

)

Restructuring and other charges

 

 

 

 

(262

)

 

 

 

(262

)

Non-GAAP research and development

$

12,471

 

 

$

12,566

 

 

$

14,299

 

 

$

51,083

 

 

$

62,254

 

 

 

 

 

 

 

 

 

 

 

GAAP sales and marketing

$

13,593

 

 

$

12,720

 

 

$

14,596

 

 

$

49,064

 

 

$

56,985

 

Stock-based compensation expense

(1,211

)

 

(1,160

)

 

(1,137

)

 

(4,106

)

 

(3,859

)

Restructuring and other charges

 

 

 

 

(198

)

 

 

 

(198

)

Non-GAAP sales and marketing

$

12,382

 

 

$

11,560

 

 

$

13,261

 

 

$

44,958

 

 

$

52,928

 

 

 

 

 

 

 

 

 

 

 

GAAP general and administrative

$

11,338

 

 

$

11,137

 

 

$

15,112

 

 

$

51,096

 

 

$

47,624

 

Stock-based compensation expense

(3,948

)

 

(4,029

)

 

(3,402

)

 

(19,125

)

 

(10,154

)

Restructuring and other charges

 

 

 

 

(102

)

 

(21

)

 

(102

)

Strategic initiative and transaction expenses

(2

)

 

(17

)

 

(1,868

)

 

(770

)

 

(2,370

)

Activist shareholder response costs

 

 

 

 

 

 

 

 

(237

)

Litigation reserves, net

 

 

 

 

(1,287

)

 

(256

)

 

(1,427

)

Non-GAAP general and administrative

$

7,388

 

 

$

7,091

 

 

$

8,453

 

 

$

30,924

 

 

$

33,334

 

ARLO TECHNOLOGIES, INC.

 

RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES (CONTINUED)

STATEMENT OF OPERATIONS DATA (CONTINUED):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

December 31,

2020

 

September 27,

2020

 

December 31,

2019

 

December 31,

2020

 

December 31,

2019

 

(in thousands, except percentage and per share data)

GAAP total operating expenses

$

40,207

 

 

$

39,370

 

 

$

(8,092

)

 

$

160,253

 

 

$

121,025

 

Separation expense

(10

)

 

(77

)

 

(154

)

 

(248

)

 

(1,913

)

Strategic initiative and transaction expenses

(2

)

 

(17

)

 

(1,868

)

 

(770

)

 

(2,370

)

Stock-based compensation expense

(7,954

)

 

(8,059

)

 

(6,906

)

 

(32,285

)

 

(20,881

)

Restructuring and other charges

 

 

 

 

(562

)

 

(21

)

 

(562

)

Litigation reserves, net

 

 

 

 

(1,287

)

 

(256

)

 

(1,427

)

Activist shareholder response costs

 

 

 

 

 

 

 

 

(237

)

Gain on sale of business

 

 

 

 

54,881

 

 

292

 

 

54,881

 

Non-GAAP total operating expenses

$

32,241

 

 

$

31,217

 

 

$

36,012

 

 

$

126,965

 

 

$

148,516

 

 

 

 

 

 

 

 

 

 

 

GAAP operating income (loss)

$

(15,669

)

 

$

(17,961

)

 

$

21,798

 

 

$

(104,864

)

 

$

(85,221

)

GAAP operating margin

(13.6

)%

 

(16.3

)%

 

17.8

%

 

(29.4

)%

 

(23.0

)%

Separation expense

10

 

 

77

 

 

154

 

 

248

 

 

1,913

 

Strategic initiative and transaction expenses

2

 

 

17

 

 

1,868

 

 

770

 

 

2,370

 

Stock-based compensation expense

8,909

 

 

9,001

 

 

7,633

 

 

35,247

 

 

22,894

 

Amortization of intangibles

237

 

 

356

 

 

373

 

 

1,306

 

 

1,517

 

Restructuring and other charges

 

 

 

 

631

 

 

44

 

 

631

 

Litigation reserves, net

 

 

 

 

1,287

 

 

256

 

 

1,427

 

Activist shareholder response costs

 

 

 

 

 

 

 

 

237

 

Gain on sale of business

 

 

 

 

(54,881

)

 

(292

)

 

(54,881

)

Non-GAAP operating loss

$

(6,511

)

 

$

(8,510

)

 

$

(21,137

)

 

$

(67,285

)

 

$

(109,113

)

Non-GAAP operating margin

(5.7

)%

 

(7.7

)%

 

(17.3

)%

 

(18.8

)%

 

(29.5

)%

 

 

 

 

 

 

 

 

 

 

GAAP provision for income taxes

$

182

 

 

$

115

 

 

$

3,525

 

 

$

625

 

 

$

4,380

 

GAAP income tax rate

(1.2

)%

 

(0.7

)%

 

15.2

%

 

(0.6

)%

 

(5.4

)%

Tax effects

(3

)

 

 

 

3,241

 

 

28

 

 

3,337

 

Non-GAAP provision for income taxes

$

185

 

 

$

115

 

 

$

284

 

 

$

597

 

 

$

1,043

 

Non-GAAP income tax rate

(3.2

)%

 

(1.5

)%

 

(1.4

)%

 

(0.9

)%

 

(1.0

)%

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss)

$

(15,210

)

 

$

(17,459

)

 

$

19,615

 

 

$

(101,251

)

 

$

(85,951

)

Separation expense

10

 

 

77

 

 

154

 

 

248

 

 

1,913

 

Strategic initiative and transaction expenses

2

 

 

17

 

 

1,868

 

 

770

 

 

2,370

 

Stock-based compensation expense

8,909

 

 

9,001

 

 

7,633

 

 

35,247

 

 

22,894

 

Amortization of intangibles

237

 

 

356

 

 

373

 

 

1,306

 

 

1,517

 

Restructuring and other charges

 

 

 

 

631

 

 

44

 

 

631

 

Litigation reserves, net

 

 

 

 

1,287

 

 

256

 

 

1,427

 

Activist shareholder response costs

 

 

 

 

 

 

 

 

237

 

Gain on sale of business

 

 

 

 

(54,881

)

 

(292

)

 

(54,881

)

Tax effects

(3

)

 

 

 

3,241

 

 

28

 

 

3,337

 

Non-GAAP net loss

$

(6,055

)

 

$

(8,008

)

 

$

(20,079

)

 

$

(63,644

)

 

$

(106,506

)

ARLO TECHNOLOGIES, INC.

 

RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES (CONTINUED)

 

STATEMENT OF OPERATIONS DATA (CONTINUED):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

December 31,

2020

 

September 27,

2020

 

December 31,

2019

 

December 31,

2020

 

December 31,

2019

 

(in thousands, except percentage and per share data)

NET INCOME (LOSS) PER DILUTED SHARE:

 

 

 

 

 

 

GAAP net income (loss) per diluted share

$

(0.19

)

 

$

(0.22

)

 

$

0.26

 

 

$

(1.30

)

 

$

(1.14

)

Separation expense

 

 

 

 

 

 

 

 

0.02

 

Strategic initiative and transaction expenses

 

 

 

 

0.02

 

 

0.01

 

 

0.03

 

Stock-based compensation expense

0.11

 

 

0.11

 

 

0.10

 

 

0.45

 

 

0.31

 

Amortization of intangibles

 

 

0.01

 

 

 

 

0.02

 

 

0.02

 

Restructuring and other charges

 

 

 

 

0.01

 

 

 

 

0.01

 

Litigation reserves, net

 

 

 

 

0.02

 

 

 

 

0.02

 

Gain on sale of business

 

 

 

 

(0.72

)

 

 

 

(0.72

)

Tax effects

 

 

 

 

0.05

 

 

 

 

0.04

 

Non-GAAP net loss per diluted share

$

(0.08

)

 

$

(0.10

)

 

$

(0.26

)

 

$

(0.82

)

 

$

(1.42

)

 

 

 

 

 

 

 

 

 

 

Shares used in computing GAAP net income (loss) per diluted share

79,164

 

 

78,662

 

 

76,090

 

 

78,084

 

 

75,074

 

Shares used in computing non-GAAP net income (loss) per diluted share

79,164

 

 

78,662

 

 

76,090

 

 

78,084

 

 

75,074

 

ARLO TECHNOLOGIES, INC.

 

SUPPLEMENTAL FINANCIAL INFORMATION

 

 

Three Months Ended

 

December 31,

2020

 

September 27,

2020

 

June 28,

2020

 

March 29,

2020

 

December 31,

2019

 

(in thousands, except headcount and per share data)

Cash, cash equivalents and short-term investments

$

206,124

 

 

$

193,611

 

 

$

205,454

 

 

$

206,582

 

 

$

256,670

 

Cash, cash equivalents and short-term investments per diluted share

$

2.60

 

 

$

2.46

 

 

$

2.64

 

 

$

2.70

 

 

$

3.37

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

$

77,643

 

 

$

56,431

 

 

$

46,466

 

 

$

61,376

 

 

$

127,317

 

Days sales outstanding

64

 

 

47

 

 

63

 

 

83

 

 

97

 

 

 

 

 

 

 

 

 

 

 

Inventories

$

64,705

 

 

$

69,038

 

 

$

65,814

 

 

$

61,027

 

 

$

68,624

 

Inventory turns

5.0

 

 

4.6

 

 

3.1

 

 

3.4

 

 

5.9

 

 

 

 

 

 

 

 

 

 

 

Weeks of channel inventory:

 

 

 

 

 

 

 

 

 

U.S. retail channel

9.2

 

 

8.4

 

 

6.6

 

 

13.7

 

 

6.3

 

U.S. distribution channel

11.7

 

 

8.6

 

 

8.4

 

 

20.3

 

 

8.0

 

APAC distribution channel

2.8

 

 

4.2

 

 

6.8

 

 

6.0

 

 

3.6

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue (current and non-current)

$

69,705

 

 

$

38,530

 

 

$

54,546

 

 

$

59,848

 

 

$

66,098

 

 

 

 

 

 

 

 

 

 

 

Cumulative registered accounts (1)

5,047

 

 

4,774

 

 

4,518

 

 

4,245

 

 

4,015

 

Cumulative paid accounts (2)

435

 

 

356

 

 

298

 

 

255

 

 

230

 

 

 

 

 

 

 

 

 

 

 

Headcount

359

 

 

358

 

 

355

 

 

356

 

 

349

 

Non-GAAP diluted shares

79,164

 

 

78,662

 

 

77,885

 

 

76,560

 

 

76,090

 

_________________________

(1)

We define our registered accounts at the end of a particular period as the number of unique registered accounts on the Arlo platform as of the end of such particular period, and includes accounts owned by Verisure S.a.r.l.. The number of registered accounts does not necessarily reflect the number of end-users on the Arlo platform, as one registered account may be used by multiple people.

 

(2)

Paid accounts worldwide measured as any account where a subscription to a paid service is being collected (either by the Company or by the Company’s customers or channel partners), plus paid service plans of a duration of more than 3 months bundled with products (such bundles being counted as a paid account after 90 days have elapsed from the date of registration). Paid accounts includes accounts transferred to Verisure S.a.r.l..

REVENUE BY GEOGRAPHY

 

 

Three Months Ended

 

Twelve Months Ended

 

December 31,

2020

 

September 27,

2020

 

December 31,

2019

 

December 31,

2020

 

December 31,

2019

 

(in thousands, except percentage data)

Americas

$

92,301

 

81

%

 

$

75,861

 

69

%

 

$

94,668

 

77

%

 

$

269,395

 

76

%

 

$

289,160

 

78

%

EMEA

15,302

 

13

%

 

28,010

 

25

%

 

19,862

 

16

%

 

61,832

 

17

%

 

57,232

 

15

%

APAC

7,233

 

6

%

 

6,365

 

6

%

 

7,883

 

7

%

 

25,927

 

7

%

 

23,615

 

7

%

Total

$

114,836

 

100

%

 

$

110,236

 

100

%

 

$

122,413

 

100

%

 

$

357,154

 

100

%

 

$

370,007

 

100

%

 

Arlo Investor Relations

Erik Bylin

[email protected]

(510) 315-1004

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Construction & Property Security Building Systems Audio/Video Internet Hardware Consumer Electronics

MEDIA:

CarLotz, Inc. Announces Fourth Quarter and Fiscal 2020 Earnings Release Date, Conference Call and Webcast

Company to Hold Conference Call on March 15, 2021

RICHMOND, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) — CarLotz, Inc. (“CarLotz” or the “Company”), a leading consignment-to-retail used vehicle marketplace, will release its fourth quarter and fiscal 2020 results after the U.S. stock market closes on March 15, 2021. The Company will hold a conference call to discuss the business update at 4:30 p.m. (Eastern Time) that day.

The U.S. toll-free dial-in for the conference call is 1-833-962-1461, and the international dial-in number is 1-929-517-0392. The Conference ID is 3417456. A live webcast of the conference call will also be available on the investor relations page of the Company’s website at https://investors.carlotz.com.

For those unable to participate in the conference call, a replay will be available after the conclusion of the call on March 15, 2021 through March 22, 2021. The U.S. toll-free replay dial-in number is 1-855-859-2056, and the international replay dial-in number is 1-404-537-3406. The replay passcode is 3417456.

About CarLotz, Inc.

CarLotz is a used vehicle consignment and Retail Remarketing™ business that provides our corporate vehicle sourcing partners and retail sellers of used vehicles with the ability to access the previously unavailable retail sales channel, while simultaneously providing buyers with prices that are, on average, below those of traditional dealerships. Our mission is to create the world’s greatest vehicle buying and selling experience. We operate a technology-enabled buying, sourcing and selling model that offers a seamless omni-channel experience and comprehensive selection of vehicles, while allowing for a fully contactless end-to-end e-commerce interface that enables no hassle buying and selling. Our proprietary Retail Remarketing™ technology provides our corporate vehicle sourcing partners with real-time performance metrics and data analytics, along with custom business intelligence reporting that enables price and vehicle triage optimization between the wholesale and retail channel. Through our marketplace model, we generate significant value for both sellers and buyers through price, selection and experience.

Investor Contact:

[email protected]

 



Amplify Energy Schedules Fourth Quarter 2020 Earnings Release and Conference Call

HOUSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) — Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) announced today that it will report fourth quarter 2020 financial and operating results before the U.S financial markets open on March 11, 2021. Following the announcement, management will host a conference call at 10:00 a.m. CT to discuss the Company’s results. Interested parties are invited to participate in the conference call by dialing (833) 883-4379 (Conference ID: 3731609) at least 15 minutes prior to the start of the call or via the internet at www.amplifyenergy.com. A replay of the call will be available on Amplify’s website or by phone at (855) 859-2056 (Conference ID: 3731609) for a fourteen-day period following the call.

About Amplify Energy

Amplify Energy Corp. is an independent oil and natural gas company engaged in the acquisition, development, exploration and production of oil and natural gas properties. Amplify’s operations are focused in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas / North Louisiana, and the Eagle Ford. For more information, visit www.amplifyenergy.com.

Investor Relations Contacts

Jason McGlynn – Chief Financial Officer
(832) 219-9055
[email protected]



TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021

TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021

-Executive Management to Host Conference Call on March 2, 2021 at 8:30 a.m. ET-

BOCA RATON, Fla.–(BUSINESS WIRE)–
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.

Conference Call & Audio Webcast Details

Date

Tuesday, March 2, 2021

Time

8:30 a.m. ET

Telephone Access: U.S. and Canada

866-665-9531

Telephone Access: International

724-987-6977

Access Code For All Callers

6184646

Live Audio Webcast

www.therapeuticsmd.com

See Home Page or “Investors & Media” Section

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call’s completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 6184646.

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefore; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and the proceeds that may be generated by such divestiture; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Women Other Health Consumer Health Managed Care

MEDIA:

Logo
Logo

FCPT Announces Acquisition of a Firestone Property for $3.5 Million

FCPT Announces Acquisition of a Firestone Property for $3.5 Million

MILL VALLEY, Calif.–(BUSINESS WIRE)–
Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership of high-quality, net-leased restaurant properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Firestone property for $3.5 million. The property is located in a strong retail corridor in Missouri and is corporate-operated under a triple net lease with approximately six years of term remaining. The transaction was priced at a 6.8% going-in cash capitalization rate, exclusive of transaction costs.

About FCPT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. Additional information about FCPT can be found on the website at www.fcpt.com.

Four Corners Property Trust:

Bill Lenehan, 415-965-8031

CEO

Gerry Morgan, 415-965-8032

CFO

KEYWORDS: California Missouri United States North America

INDUSTRY KEYWORDS: REIT Restaurant/Bar Retail Commercial Building & Real Estate Construction & Property

MEDIA:

Oncocyte to Begin Trading on the Nasdaq Stock Market on March 8, 2021

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has been approved for listing on the Nasdaq Global Market. The Company’s shares will continue to trade under its current symbol, “OCX,” with trading on Nasdaq expected to commence at the open of market on Monday, March 8, 2021.   Oncocyte’s shares will continue to trade on the NYSE American Exchange until the close of trading on Friday, March 5, 2021.

“Listing on the Nasdaq, a market known as the home of innovative and growing global companies, is an important milestone for our company,” said Ron Andrews, Chief Executive Officer of Oncocyte. “As we continue our growth, we believe there are many potential benefits of listing on this well-respected global market, including increased visibility, better market liquidity, exposure to more institutional investors, and ultimately improved shareholder value. Also, the prospect of being included in one or more Nasdaq healthcare indexes is another significant potential advantage of listing.”

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO, the Company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company also plans to continue with the development of DetermaMx™ as it seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx, DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation.

Oncocyte Forward Looking Statements

Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the potential benefits of listing on the Nasdaq Global Market, unexpected delays, unexpected expenditures, indemnities or other liabilities, or other unanticipated difficulties resulting from technology transfers, commercial plans, invalidation, termination or reduction of any licensed intellectual property rights, or infringement of third party intellectual property rights, acquisitions, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for Oncocyte or any distributor, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our or any distributor’s financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor’s supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]